Corbus (CRBP) CEO Yuval Cohen Sells 17,000 Shares

What Happened

• Yuval Cohen, CEO of Corbus Pharmaceuticals Holdings, sold 17,000 shares on 2026-08-07 in an open-market/private sale (Form 4 filed 2026-08-10). The reported weighted-average price was $10.08, for total proceeds of roughly $171,396. The sale was executed pursuant to a Rule 10b5-1 trading plan.

Key Details

• Transaction date: 2026-08-07; Form 4 filed: 2026-08-10.
• Shares sold: 17,000; weighted-average price reported: $10.08 (sales occurred at prices ranging $10.00–$10.18).
• Ownership after transaction: not specified in the provided summary; filing notes include 138,049 unvested RSUs as part of the reporting person’s holdings.
• Footnotes:
  • F1: Sale effected under a 10b5-1 plan adopted March 11, 2026.
  • F2: Price is a weighted average; individual sale prices ranged $10.00–$10.18 (reporting person can provide per-price breakdown on request).
  • F3: Ownership figures include 138,049 unvested RSUs subject to prior vesting schedules.
• Filing timeliness: Form 4 was filed three days after the trade; no late-filing flag was provided in the supplied data.

Context

• This was a sale (S), which is commonly routine and may be driven by pre-set trading plans (as here). Sales convey less direct insight into an insider’s view of company prospects than purchases. The 10b5-1 plan note indicates the trades were pre-arranged, which can reduce the inference that the sale was based on non-public information.